Scieucre Pharma US develops, commercialise and distribute finished products or dossiers (eCTD format) for registration under supply contracts.

Sciecure Pharma is focussed on the continued growth of the company and the on going introduction of new products and services, by fostering collaborations and strategic partnerships that enable the company to provide solutions for the US and international markets.

In addition to this organic growth, Sciecure Pharma seek to engage the market via acquisition and in-licensing of established products, while looking for new opportunities and therapies to the mutual benefit of both business partners and customers.

1. Marketing Authorization (ANDA) of Budesonide Capsule 3mg is granted by US FDA.